

**Guideline Committee Meeting 10**

**Asthma management**

**Date and Time:** Tuesday 14 June 2016, 10:00-16:00

**Place:** Boardroom, NGC, 180 Great Portland Street, London, W1W 5QZ

**Minutes:** Confirmed

**Present:**

**GC Members**

John Alexander, Chair, Consultant in Paediatric Respiratory & Paediatric Intensive Care, Royal Stoke University Hospital

Noel Baxter, General Practitioner, NHS Southwark CCG

Andrew Bush, Professor of Paediatrics and Head of Section, Royal Brompton and Harefield NHS Foundation Trust

Susan Frost, Lead Respiratory Nurse Specialist, Birmingham Children's Hospital

Chris Griffiths, Principal and in General Practice and Professor of Primary Care, Queen Mary University Hospital of London

Helen Haley, Pharmacist in Child Health, University Hospitals of North Midlands

Val Hudson, Patient member

Matt Masoli, Consultant Respiratory Physician, Plymouth Hospitals NHS Trust

Abigail Moore, Sp Trainee, RCP Clinical Fellow

Nicola Mundy, Patient member

Prunella Neale, Practice Nurse, Herschel Medical Centre

Ellen Nicholson, Senior Respiratory Nurse Specialist, Homerton University Foundation Trust

Stephen Scott, Consultant Respiratory Physician, Countess of Chester Hospital

**NICE**

Gareth Haman, Senior Medical Editor

**NCGC**

Katie Broomfield, Document Editor/Process Assistant (notes)

James Gilbert, Research Fellow

Alex Haines, Senior Health Economist

Bernard Higgins, Clinical Director

Ben Mayer, Research Fellow

**Apologies:**

Samantha Jones, Project Manager, NGC

Caroline Keir, Guidelines Commissioning Manger, NICE

Sharon Swain, Senior Research Fellow, NGC

Claire Wallnutt, Information Scientist, NGC

## Notes

### 1. Welcome, apologies and introductions

The Chair welcomed the group to the tenth meeting of this guideline committee. Apologies were received from SJ,CK, SS and CW.

The minutes from GC9 were confirmed as a true and accurate record of the meeting.

### 2. Declarations of interest

The following new declarations were received for this meeting:

<b>Committee Declarations of Interest</b>			
N.B. The Chair and Committee members were recruited to this guideline using NICE DOI policy published Sept 2014.			
<b>Insert initials</b>	<b>Declaration</b>	<b>Classification (as per the NICE DOI policy wording*)</b>	<b>Chair's action</b>
EN	Speaker at Teva Respiratory Masterclass on Diagnostic Tools for Respiratory Diseases 11/06/2016 at Hadley Wood receiving no financial incentive for participation. Teva have combined this Masterclass with Napp Pharmaceutical Group Ltd.	Personal non-financial specific	Declare and participate
AM	Grant received from Macmillan for a project on breathlessness in cancer patients.	Personal financial non-specific	Declare and participate
StS	I am secretary of the North West Thoracic Society. This position means I introduce speakers at the meetings for respiratory physicians in the North West. I have no direct pecuniary benefit from this and it is a voluntary/nominated position. It is a purely educational meeting with no presentations or input from pharma into the content of the meeting. However Boehringer do provide funding for the venue and catering but have no input into the speakers who are decided on by the secretary team.	Personal non-financial specific	Declare and participate
NICE DOI policy classifications are:			
<ul style="list-style-type: none"> <li>• Personal financial specific</li> <li>• Personal financial non-specific</li> <li>• Personal non-financial specific</li> <li>• Personal non-financial non-specific</li> <li>• Non-personal financial specific</li> <li>• Non-personal financial non-specific</li> </ul>			

## Notes

3. **Review LETRs: Question 4 and Question 8**

The group discussed the LETRs for third-line preventer and risk stratification. Comments and minor amendments were made where required.

4. **Evidence review: Question 7: Adherence**

BM presented the clinical evidence for the Question 7 review. There was no economic evidence. The GC discussed the evidence.

5. **Evidence review: Question MART therapy**

JG presented the clinical evidence for the Question 12 review. AH presented the economic evidence. The GC discussed the evidence.

6. **Preliminary economic model results**

AH presented the preliminary economic model result for LABA versus LTRA. The GC discussed the result.

7. **Any other business**

Next steps were discussed and action points assigned.

**Date, time and venue of the next meeting**

GC11: Tuesday 12 July 2016, 1000-1600, Boardroom, NGC, 180 Great Portland Street, London W1W 5QZ